Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ambitions got a big boost from the biotech’s market debut.
Sergey Brin
Photographer: Will Oliver/EPA/Bloomberg
His nonprofit, Catalyst4, is the drug developer’s largest shareholder, and two leaders of his family office sit on the board, including one of MapLight’s co-founders. The nonprofit currently controls a 60.7% majority voting stake in MapLight, although that is expected to decline to 36.8% after the IPO, according to filings.
The shares rose 7.9% to $18.34 in the company’s first day of trading in New York, valuing Catalyst4’s ...
